Title | Pharmacological distinction between soluble and transmembrane adenylyl cyclases. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Bitterman JL, Ramos-Espiritu L, Diaz A, Levin LR, Buck J |
Journal | J Pharmacol Exp Ther |
Volume | 347 |
Issue | 3 |
Pagination | 589-98 |
Date Published | 2013 Dec |
ISSN | 1521-0103 |
Keywords | Adenylyl Cyclase Inhibitors, Adenylyl Cyclases, Cells, Cultured, Cyclic AMP, Dose-Response Relationship, Drug, Enzyme Inhibitors, HEK293 Cells, Humans, Membrane Proteins, Signal Transduction, Subcellular Fractions, Substrate Specificity |
Abstract | The second messenger cAMP is involved in a number of cellular signaling pathways. In mammals, cAMP is produced by either the hormonally responsive, G protein-regulated transmembrane adenylyl cyclases (tmACs) or by the bicarbonate- and calcium-regulated soluble adenylyl cyclase (sAC). To develop tools to differentiate tmAC and sAC signaling, we determined the specificity and potency of commercially available adenylyl cyclase inhibitors. In cellular systems, two inhibitors, KH7 and catechol estrogens, proved specific for sAC, and 2',5'-dideoxyadenosine proved specific for tmACs. These tools provide a means to define the specific contributions of the different families of adenylyl cyclases in cells and tissues, which will further our understanding of cell signaling. |
DOI | 10.1124/jpet.113.208496 |
Alternate Journal | J. Pharmacol. Exp. Ther. |
PubMed ID | 24091307 |
PubMed Central ID | PMC3836311 |
Grant List | T32 GM073546 / GM / NIGMS NIH HHS / United States R01 GM062328 / GM / NIGMS NIH HHS / United States R01 HD059913 / HD / NICHD NIH HHS / United States HD059913 / HD / NICHD NIH HHS / United States GM62328 / GM / NIGMS NIH HHS / United States |